The U.S. House Oversight Committee decided to subpoena AbbVie Inc. to seek documents on the drugmaker’s blockbuster treatments, Humira and Imbruvica, as part of an investigation into drug pricing practices.
U.S. prosecutors are pursuing possible penalties of nearly $13 billion to resolve investigations of OxyContin maker Purdue Pharma after uncovering evidence of criminal and civil misconduct stemming from the company’s alleged role in fueling the nation’s opioid crisis, people familiar with the matter said.
Medical diagnostic firm PerkinElmer Inc. faces a federal investigation into the company’s role in an alleged Medicare fraud involving tens of thousands of unnecessary genetic cancer tests, according to three sources with knowledge of the probe and documents reviewed by Reuters.
As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.
A federal judge tossed out whistleblower lawsuits alleging that pharmaceutical giants Eli Lilly and Bayer used nurses to illegally boost sales of various prescription drugs in a kickback scheme.
Mylan NV agreed to settle U.S. SEC charges that the company hid from investors the impact of a federal probe into the drugmaker’s overbilling the government for the EpiPen allergy treatment.
Insys Therapeutics Inc. agreed to pay $225 million and an operating unit will plead guilty to fraud to settle probes into their payment of kickbacks to induce doctors to prescribe highly addictive opioids, the U.S. Department of Justice said.
Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients’ out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their medications.
An Olympus Corp. subsidiary pleaded guilty and agreed to pay $85 million to resolve charges of failure to file reports with U.S. regulators regarding infections connected to its duodenoscopes while continuing to sell the medical devices used to view the gastrointestinal tract.